Cedars-Sinai Medical Center

Cedars-Sinai Medical Center, a California-based non-profit academic medical center headquartered in West Hollywood, acts as a prime recipient on federal grants and a prime contractor on federal research awards, with a secondary role as a subcontractor to other research institutions. The institution operates primarily in the biomedical research space—specifically genomics research, complex data analysis and integration of large-scale datasets, translational medicine across cardiovascular and oncology domains, and clinical research supporting NIH-funded scientific investigation.

Cedars-Sinai is not an SBA-certified contractor and does not operate under set-aside vehicles; it competes in full-and-open federal research award processes. The vendor's federal footprint is overwhelmingly grant-centric rather than contract-centric. Of 1,194 total awards spanning 50 years, 73 percent are prime awards (contracts, IDVs, and grants combined); 27 percent are subawards. The prime-versus-sub split masks a critical distinction: most prime awards are federal research grants, not procurement contracts. Cedars-Sinai holds one significant federal contract IDV—a $500 million single-award indefinite delivery vehicle from the National Heart, Lung and Blood Institute for the Trans-Omics for Precision Medicine Centralized Omics Resource, with task orders available through September 2033 for genomic data analysis and health dataset integration work. Two additional parent vehicles carry minimal transactional volume (under $100 thousand combined). Most of the vendor's federal footprint consists of competitive project grants and cooperative agreements.

Customer concentration is extreme and driven by the National Institutes of Health. The top five NIH component institutes account for approximately 55 percent of recent award counts. The National Heart, Lung and Blood Institute (NHLBI) dominates on potential value, anchoring $1.01 billion of the vendor's combined $1.02 billion in awards; the National Cancer Institute contributes 169 awards with $6.7 million in combined potential value. The disparity reflects the Trans-Omics for Precision Medicine IDV ceiling, which alone dwarfs the rest of the portfolio. Outside NIH, activity is sparse: the Defense Health Agency and National Science Foundation represent secondary customers, each accounting for dozens of recent project grants in the low millions.

Activity has accelerated in the past four years, growing from 73 awards in 2022 to 152 in 2024, then declining to 97 in 2026. Critically, 118 awards (combined potential value $3.5 million) face ultimate completion in the next 24 months, signaling substantial grant recompete exposure. SCI data reveal minimal service-contract footprint: only four prime and three sub SCI records spanning FY2022–FY2025, with zero invoiced revenue and negligible FTE reporting. This signals that Cedars-Sinai's federal work is almost entirely grant-funded research rather than service procurement. The vendor operates Pasadena Hospital Association as a subsidiary.

Cedars-Sinai's federal grant work centers on precision medicine, translational research, and mechanistic biology. Representative prime grants include a $1.283 million NIDDK award for the Cedars-Sinai Digestive Diseases Research Center (a multidisciplinary research hub with $26.1 million in total peer-reviewed funding, 37 percent from NIDDK); a $4.492 million National Institute on Aging cooperative agreement for the Microvascular Aging Effects – Women's Evaluation of Systemic Aging Tenacity in Heart, Brain and Frailty (MAE-WEST HBF) specialized center; a $1.569 million NIA award investigating estrogen signaling in UTI-related delirium in postmenopausal women; and a $3.48 million National Institute of Environmental Health Sciences award developing AI and machine learning methods for large-scale epidemiological studies using patient-generated medication adherence and tolerability reports. The vendor also receives substantial project-grant support from the Defense Health Agency (DHA), including a $2.685 million award on disseminated tumor cell biology and a $1.25 million award on ONECUT2 and prostate cancer. In its subrecipient role, Cedars-Sinai provides data analysis, biospecimen and tissue sourcing, clinical trial site coordination, and genomic sequencing services to NIH lead institutions (UCLA, Columbia, University of Pennsylvania, Mayo Clinic, and others). The vendor is frequently a sub-recipient on cooperative agreements and R01 research grants where its contributions include patient recruitment, clinical assessment, site-specific regulatory oversight, and specialized biomarker or imaging analysis.

The vendor's teaming posture is predominantly hierarchical rather than collaborative at the prime level. As a prime, Cedars-Sinai generally builds delivery through its own institutional research infrastructure and hired personnel; subcontracting activity on prime grants is minimal. As a subrecipient on NIH grants, however, Cedars-Sinai routinely partners with large research universities and medical centers, contributing domain expertise in genomics, clinical trial management, and tissue banking. The subrecipient footprint includes named collaborations with UC San Diego, UCLA, Stanford, Caltech, University of Pennsylvania, Columbia University, Mayo Clinic, Harvard Partners, and UCSF, among others. This pattern is consistent with Cedars-Sinai's positioning as a specialized research hospital contributing clinical, biospecimen, and computational capabilities to larger translational research networks rather than as a prime lead on multi-institutional studies.